A quantitative analysis of kinase inhibitor selectivity

Nature Biotechnology

Volumn 26, Issue 1, 2008, Pages 127-132

  Karaman, Mazen W ^a   Herrgard, Sanna ^a   Treiber, Daniel K ^a   Gallant, Paul ^a   Atteridge, Corey E ^a   Campbell, Brian T ^a   Chan, Katrina W ^a   Ciceri, Pietro ^a   Davis, Mindy I ^a   Edeen, Philip T ^a   Faraoni, Raffaella ^a   Floyd, Mark ^a   Hunt, Jeremy P ^a   Lockhart, Daniel J ^a   Milanov, Zdravko V ^a   Morrison, Michael J ^a   Pallares, Gabriel ^a   Patel, Hitesh K ^a   Pritchard, Stephanie ^a,b   Wodicka, Lisa M ^a   Zarrinkar, Patrick P ^a   more..

^a Ambit Biosciences   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ANALYSIS; PROTEINS;

HUMAN PROTEIN KINOME; INTERACTION PATTERNS; KINASE INHIBITOR SELECTIVITY;

ENZYME INHIBITION;

PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME INHIBITOR COMPLEX; ENZYME SPECIFICITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

BINDING SITES; ENZYME ACTIVATION; HUMANS; PHOSPHOTRANSFERASES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEOME; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38049018155     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1358     Document Type: Article

References (33)

1. Baselga, J. Targeting tyrosine kinases in cancer: the second wave. Science 312, 1175-1178 (2006).
2. Sebolt-Leopold, J.S. & English, J.M. Mechanisms of drug inhibition of signalling molecules. Nature 441, 457-462 (2006).
3. Garber, K. The second wave in kinase cancer drugs. Nat. Biotechnol. 24, 127-130 (2006).
4. Knight, Z.A. & Shokat, K.M. Features of selective kinase inhibitors. Chem. Biol. 12, 621-637 (2005).
5. Bain, J., McLauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 371, 199-204 (2003).
6. Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
7. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
8. Carter, T.A. et al. Inhibition of drug-resistant mutants of ABL, KIT and EGFR Kinases. Proc. Natl. Acad. Sci. USA 102, 11011-11016 (2005).
9. Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
10. Lombardo, L.J. et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661 (2004).
11. Sun, L. et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116-1119 (2003).
12. Lowinger, T.B., Riedl, B., Dumas, J. & Smith, R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 8, 2269-2278 (2002).
13. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
14. Flaherty, K.T. Sorafenib in renal cell carcinoma. Clin. Cancer Res. 13, 747s-752s (2007).
15. Wilhelm, S.M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004).
16. Buchdunger, E. et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145 (2000).
17. Heinrich, M.C. et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932 (2000).
18. Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052-1056 (2001).
19. Giles, F.J. et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109, 500-502 (2007).
20. Chen, J., Zhang, X. & Fernandez, A. Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics 23, 563-572 (2007).
21. Ohren, J.F. et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 11, 1192-1197 (2004).
22. Cuenda, A. et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229-233 (1995).
23. Morin, M.J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19, 6574-6583 (2000).
24. Sako, T., Tauber, A.I., Jeng, A.Y., Yuspa, S.H. & Blumberg, P.M. Contrasting actions of staurosporine, a protein kinase C inhibitor, on human neutrophils and primary mouse epidermal cells. Cancer Res. 48, 4646-4650 (1988).
25. Vieth, M. et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim. Biophys. Acta 1697, 243-257 (2004).
26. Allen, L.F., Lenehan, P.F., Eiseman, I.A., Elliott, W.L. & Fry, D.W. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin. Oncol. 29, 11-21 (2002).
27. Jirousek, M.R. et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15- tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J. Med. Chem. 39, 2664-2671 (1996).
28. Trudel, S. et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105, 2941-2948 (2005).
29. Bach, S. et al. Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280, 31208-31219 (2005).
30. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007).
31. Melnick, J.S. et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc. Natl. Acad. Sci. USA 103, 3153-3158 (2006).
32. Sheinerman, F.B., Giraud, E. & Laoui, A. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. J. Mol. Biol. 352, 1134-1156 (2005).
33. Graczyk, P.P. Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. J. Med. Chem. 50, 5773-5779 (2007).